SCHEMBL6830982

SCHEMBL6830982

COc1ccc(S(=O)(=O)Nc2ccc(C(=CC(=O)NO)c3ccccc3)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.63
HDAC4 P56524 5/20 0.63
HDAC3 O15379 4/20 0.59
HDAC7 Q8WUI4 4/20 0.59
HDAC2 Q92769 4/20 0.59
HDAC10 Q969S8 4/20 0.59
HDAC11 Q96DB2 4/20 0.59
HDAC8 Q9BY41 4/20 0.59
HDAC6 Q9UBN7 4/20 0.59
HDAC9 Q9UKV0 4/20 0.59
HDAC5 Q9UQL6 4/20 0.59
PGR P06401 1/20 0.58
ALDH1A1 P00352 3/20 0.56
LIMK2 P53671 1/20 0.56
LMNA P02545 2/20 0.54
USP2 O75604 1/20 0.54
ALOX15 P16050 1/20 0.54
TCF4 P15884 1/20 0.53
CTNNB1 P35222 1/20 0.53
GAA P10253 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6830979 1.00 HDAC1 (0.63) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL6834529 0.90 TCF4 (0.65) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL6834490 0.90 TCF4 (0.65) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL6834488 0.90 TCF4 (0.65) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL6834224 0.90 LIMK2 (0.62) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL6834222 0.90 LIMK2 (0.62) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL6834493 0.86 TCF4 (0.69) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL6834354 0.82 HDAC1 (0.63) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL6834353 0.82 HDAC1 (0.63) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL6833460 0.80 TCF4 (0.69) PGRALDH1A1LIMK2LMNATCF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040029928-A1 Novel propenohydroxamic acid derivatives WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2004-02-12 US disclosed
EP-1314721-A1 NOVEL PROPENOHYDROXAMIC ACID DERIVATIVES WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029928-A1 Novel propenohydroxamic acid derivatives TNF, SI, HDGF HDAC1 920/4885HDAC4 1201/4885HDAC3 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.